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Since the identification of the regulatory T-cell (Treg)-associated transcription factor
Foxp3, there have been intensive research efforts to understand its biology and roles
in maintaining immune homeostasis. It is well established that thymic selection of a
repertoire of self-reactive Foxp3+ T-cells provides an essential mechanism to minimize
reactions to self-antigens in the periphery, and thus aid in the prevention of autoimmunity.
It is clear from both genetic and immunological analyses of juvenile idiopathic arthritis
(JIA) patients that T-cells have a strong role to play in both the initiation and propagation
of disease. The current paradigm is to view autoimmunity as a consequence of an
imbalance between inflammatory and immunoregulatory mechanisms. This view has
led to the assigning of cells and inflammatory mediators to different classes based
on their assumed pro- or anti-inflammatory roles. This is typically reported as ratios
of effector T-cells to Treg cells. Problematically, many analyses are based on static
“snapshots-in-time,” even though both mouse models and human patient studies have
highlighted the dynamic nature of Foxp3+ T-cells in vivo, which can exhibit plasticity and
time-dependent functional states. In this review, we discuss the role of Foxp3 dynamics
in the control of T-cell responses in childhood arthritis, by reviewing evidence in humans
and relevant mouse models of inflammatory disease. Whilst the cellular dynamics of Treg
have been well evaluated—leading to standard data outputs such as frequency, quantity
and quality (often assessed by in vitro suppressive capacity)—we discuss how recent
insights into the molecular dynamics of Foxp3 transcription and its post-translational
control may open up tantalizing new avenues for immunotherapies to treat autoimmune
arthritis.
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AIMS AND SCOPE
The aim of this article is to provide an overview of the literature reporting Foxp3+ Regulatory
T cell (Treg) cell biology in juvenile idiopathic arthritis (JIA) and place this in the context of recent
advances in understanding basic Treg biology. For review of JIA Treg biology, a defined Pubmed
search was performed with the following terms: “Treg” OR “Foxp3” OR “Regulatory T cell” AND
“Juvenile Idiopathic Arthritis”1. What is clear from these papers is that there has been great industry
in elucidating Treg and effector T-cell biology and relating this to disease mechanisms from cellular
viewpoints. This article aims to build on this body of knowledge by detailing how recent new
1Search date July 10th 2018.
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approaches are giving fresh insight into the molecular control
of Foxp3 and the dynamics of T-cell regulation. It is hoped that
this approach may help human immunologists to disambiguate
markers used to identify Treg [e.g., CD25 and CD127
expression (1)] and stimulate fresh thinking about Foxp3-
mediated regulatory mechanisms in JIA.
INTRODUCTION
Foxp3 is essential for T-cell homeostasis and is considered one
of the main drivers of Regulatory T-cell (Treg) differentiation
(2). Mutations in the FOXP3 gene in humans cause the complex
multiorgan autoimmune disease, Immune Dysregulation
Polyendocrinopathy Enteropathy X-linked syndrome (IPEX)
(3). This condition parallels the Scurfy mouse (4), where a
two base-pair insertion in the murine Foxp3 gene results in
a truncated form of Foxp3 protein (5) and loss of immune
regulation. Scurfy mice typically die within 3 weeks, highlighting
that loss of function of Foxp3 is not compatible with long-term
survival. A Treg lineage (6) interpretation of these findings is that
Foxp3 mutations lead to loss of a dedicated line of suppressor T-
cells, presumably because Foxp3 can no longer imprint the Treg
suppressive phenotype (7). Treg are often divided into thymic
and peripheral subsets, based on their sites of differentiation.
Thymic Treg are self-reactive, and are important components
of central tolerance. Peripheral Treg are thought to arise in
response to innocuous antigens, and may be important for
tolerance to dietary antigens or commensal bacteria. Together
these subsets work to exert dominant tolerance to both self and
foreign antigens (8).
Given the importance of Foxp3 to immune homeostasis and
Treg biology, it has become a focal point of immunological
research into diseases arising due to dysregulated T-cell
responses, such as JIA. JIA is the most common form of
autoimmune rheumatic disease with a prevalence in the region
of one in a thousand in children under 16 years of age
(9). JIA is a heterogeneous group of conditions, covering
all forms of arthritis commencing in children under 16
years of age and lasting for at least 6 weeks duration (10).
Although heterogeneity represents a challenge to translate basic
immunological findings from animal models to JIA, access to
the site of inflammation provides precious material for studying
underlying immunological mechanisms.
GENETICS OF JIA POINT TO T-CELL
REGULATION
Genetic association studies of JIA (incorporating the most
common subtypes of disease) clearly highlight a key role for genes
involved in the immune system, particularly those involved in the
regulation of T-cell biology (11). Unsurprisingly, the strongest
association is with human leukocyte antigen (HLA) alleles.
This is a common occurrence in autoimmune diseases (12),
which may be due to the finding that self-antigen-specific Treg
selection is HLA allele-dependent and modulates susceptibility
to autoimmunity (13). There also exists a striking association
with genes involved in the molecular control of Treg biology.
Although nine single nucleotide polymorphisms (SNPs) within
the human FOXP3 gene show no significant associations to
JIA (14) (suggesting these do not impact on FOXP3 in JIA),
a key FOXP3-binding partner, Runt-related transcription factor
1 (RUNX1), is, however, significantly associated. In non-Foxp3
expressing T-cells, RUNX1 enhances interleukin (IL)2 expression
through direct binding of the IL2 promoter in activated CD4+
T-cells (7). However, in the context of Foxp3 expression,
functional studies in mice have shown that Runx1 and Foxp3
form molecular complexes which lead to the repression of
Il2 and interferon gamma (Ifng), and upregulation of Treg
effector molecules, such as CD25 and cytotoxic lymphocyte
antigen 4 (CTLA-4) (7). Thus, Foxp3 can re-direct the molecular
machinery involved in T-cell activation in order to drive a T-
cell-intrinsic suppressive programme. Whilst Foxp3 expression
has been mainly studied in the context of Treg generation (15),
the T-cell-intrinsic functions of FOXP3 expression during either
T-cell activation (which is considered transient, but can have
functional consequences for effector T-cells (16)) or peripheral
(p)Treg generation in JIA remain unknown.
In addition to RUNX1, genes encoding proteins involved in
cytokine signaling pathways that are critical to the development
of FOXP3+ T-cells are also significantly associated. IL2RA
[gene encoding CD25, the original Treg marker (17)] and the
IL2/IL21 cytokine locus display significant disease associations
(11). Furthermore, deficiency in the IL-2 signaling molecule
signal transducer and activator of transcription (STAT)5b has
been reported in patients with JIA (18). IL-2 signaling is critical
for the survival and fitness of Treg in the periphery (19) and
is sensed by the conserved non-coding sequence 2 (CNS2)
of the Foxp3 gene to maintain Treg cell identity (20). These
findings suggest that molecular tuning of Foxp3 transcription and
function not only have genetic associations but may represent a
new avenue through which to further our understanding of the
pathogenesis of JIA.
FOXP3+ TREG CELL BIOLOGY IN JIA
Analysis of Treg cells identified by CD25 expression has shown
that such cells are enriched at the site of inflammation in JIA (21).
The authors further dissected whether CD25+ T-cells show any
relationship to disease severity. Here analysis of the oligoarticular
(O)-JIA subset of patients is very useful since the O-JIA patient
group can have divergent clinical outcomes (22). The “persistent”
O-JIA subtype presents with a mild, remitting form of disease,
which can spontaneously resolve. However, there exists a subset
of O-JIA patients in which the disease progresses and arthritis
extends to include an increasing number of joints, which are
referred to as extended O-JIA patients. These divergent forms
of O-JIA have allowed translational immunologists to compare
between different severities of disease, which has proven powerful
for correlating the role of Treg and T-helper subsets in JIA with
measurable disease outcomes. Interestingly, CD25+ Treg cells are
present in increased numbers within the joints of JIA patients
with the milder persistent form of O-JIA compared to those
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with the more severe form of extended O-JIA disease (21). These
findings were further verified using the “gold standard” Treg
marker, FOXP3, in a separate patient cohort (23). Interestingly,
both of these studies highlighted that compared to Treg in blood,
Treg at the inflamed site were not only increased in proportion
but they also displayed increased FOXP3 protein expression at
the single cell level (24). These seemingly paradoxical findings of
a vastly increased Treg signature at inflamed sites suggest that
Treg presence alone may not detail the whole picture. Indeed,
many subsequent studies have highlighted that the balance of
effector and regulatory mechanisms may be a major influencer
of disease outcome. Evidence to support this in JIA comes from
findings that Th17 cells, which drive chronic arthritis via a
cellular cascade (25), are also increased in the synovial fluid (SF)
of JIA patients and display a reciprocal relationship with Treg
(23) or FOXP3 expression levels (24).
Alterations in Treg phenotypes are likely influenced by the
joint environment (26, 27). Firstly, Treg from SF are susceptible
to the downregulation of FOXP3 following removal from the
inflamed environment (26), which can be prevented by addition
of synovial fluid to cultures. Furthermore, analysis of thymic
Treg output [which has been shown to be altered in adult
rheumatic disease (28)] revealed that JIA patients are no different
from controls (29), suggesting that the quantity of thymic Treg
generation may be unaffected. Furthermore functional studies on
Treg from JIA patients suggest no qualitative difference in their
ability to suppress T-cell responses (30).
As to what may explain disease in the presence of increased
Treg frequency, investigators have looked at the effector T-cells.
In vitro suppression assays have shown that Treg from the blood
and SF of JIA patients display similar abilities in regulating the
proliferation of conventional T-cells (Tconv) from the peripheral
blood environment (30, 31). However, Tconv from the inflamed
site showed resistance to suppression by Treg. Neat follow up
in vitro studies to this have gone on to show that this resistance to
suppression could be overcome by the blocking of inflammatory
cytokines such as tumor necrosis factor alpha (TNFα) (32, 33),
which may provide a potential mechanism of action for biologics
used to treat JIA. However, whilst these studies suggest that SF
Tconv may be more resistant to regulation in vitro, it is unknown
whether Tconv are resistant to regulation in vivo. In particular,
analysis of Ki67+ (marker of cell proliferation) T-cells in the
joints of JIA patients suggests a more complex picture, since
the majority of dividing cells in the joint are Treg or Treg-
like [as evidenced by hypomethylation of the Foxp3 gene (27)].
Nonetheless a consensus has built based on the aforementioned
work that site-specific Treg and Tconv interactions play central
roles in the pathogenesis of JIA (Figure 1).
DYNAMICS AND CLONAL RELATIONSHIPS
BETWEEN FOXP3+ AND FOXP3− T-CELLS
IN JIA
Recent advances in sequencing technologies has allowed the
profiling of the T-cell receptor (TCR) repertoires of Treg in
JIA, which can be used to assess the relative clonal sharing
FIGURE 1 | Cellular seesaw view of Treg and Th17 cells in JIA pathogenesis.
In blood, immune relationships are balanced and Treg can regulate effector
T-cells. In synovial fluid, Treg are increased at the inflamed site but show a
reciprocal relationship to Th17 cells. This suggests that the balance of Th17 to
Treg cells may influence disease course, likely through increased production of
inflammatory mediators. Treg may be dysfunctional, either through loss of
Foxp3 and lineage stability, or are unable to regulate Tconv at the site of
inflammation due to the release of inflammatory cytokines such as TNFα.
Current strategies have aimed to tip the balance of this system in order to
promote tolerance over autoimmunity.
between different CD4+ T-cell subsets and provide great insight
into cellular dynamics. Deep sequencing of TCRβ chains has
highlighted more restricted and oligoclonal repertoires in SF T-
cells compared to blood (26, 34). Comparison between controls
and JIA peripheral blood Treg suggests that JIA patients have
skewing of both blood and SF TCR repertoires (34). This
skewing of the repertoire could arise from recirculation of T-cells
between blood and SF (35), but potentially could be an important
biomarker for treatment. Indeed, animal studies have shown
that bone marrow transplantation following peptidoglycan-
induced arthritis revealed that Treg from the graft repopulate
the immune system and show improved repertoire diversity
(36). In fact, transfer of additional Foxp3-GFP+ T-cells together
with the bone marrow transfer graft did not induce additional
clinical improvement but moreover delayed TCR repertoire
diversification, cautioning the use of Treg transfers in such
settings. This is likely due to the fact that these additional
Treg suppress T-cell proliferation, thus delaying expansion of
donor-derived T-cells. In addition, the authors were able to
show that JIA patients undergoing haematopoietic stem cell
transfers also showed improved Treg diversity. These findings
suggest that an immune reset provides an opportunity for graft-
derived cells to regulate the autoimmune response, likely due
to alterations in T-cell dynamics. Indeed, the SF environment
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appears to drive dynamic changes in Treg expression of key
molecules. TCR repertoire analysis of SF T-cells expressing
different combinations of CD25 and FOXP3 have shown that
there is remarkable clonal sharing between CD25+FOXP3−,
CD25+FOXP3+, and CD25−FOXP3+ T-cells within the joint
(26). These findings suggest that CD25 and FOXP3 expression
within Treg-like populations may be dynamic within the
joint; however, this does not preclude the possibility that
CD25+FOXP3- T-cells also contain recently activated effector T-
cells. Indeed, a thorough dissection of these populations would
give useful insight to the dynamics of T-cell activation and
FOXP3 expression in JIA. Given this observation, it will be
intriguing for future studies to interrogate relationships between
the TCR repertoires of Th17 and Treg cells within the joints
of O-JIA patients, in order to establish whether the reciprocal
relationship arises from discrete clones, or whether Th17/Treg
plasticity is an important mechanism. For instance hybrid IL-
17A+ FOXP3+ Treg, identified by expression of CD161, are
significantly enriched at the site of inflammation (37, 38),
and repertoire overlap between CD161+ Treg and Tconv as
a proportion of CD161+ SF Treg was in the region of 20–
30% (38), suggesting plasticity of T-cell responses within the
joint. In summary, what these papers clearly show is that the
joint environment is highly dynamic, and that snapshot in time
analyses may obscure observations that may be accounted for by
cellular and molecular dynamics.
MOLECULAR DYNAMICS REGULATE
FOXP3+ T-CELL BIOLOGY
Whilst Foxp3 expression is used to define Treg subsets and is
considered a stable marker of Treg cells, the clonal relationships
between Treg and Tconv by TCR sequencing can also be
explained by taking a molecular perspective (6). For instance, we
have recently generated a new reporter system called Timer of cell
kinetics and activity (Tocky) [(39); Figure 2A], which highlights
a feedback control role for Foxp3 in regulating T-cell responses.
This approach places the emphasis on the molecular dynamics
of the system, with a reduced focus on cellular categorization,
which can unnecessarily constrain analysis, particularly for high-
dimensional data sets.
TIMER OF CELL KINETICS AND ACTIVITY
(TOCKY) SYSTEM
Tocky reporter system uses a short-lived fluorescent Timer
protein (40) to capture the activity of the Foxp3 gene. Timer
protein exhibits an initial blue fluorescent form, with an
approximate half-life of 4 h in Foxp3-Tocky mice. Timer protein
undergoes spontaneous and irreversible maturation into a red
fluorescent form which has a half-life in the region of 5 days
(41). Foxp3-Tocky therefore allows the detection of biologically
important Foxp3 gene settings. New Foxp3 expressers are
identified in Foxp3-Tocky mice by virtue of their pure blue
fluorescence upon expression of the Timer gene, which is under
the control of the Foxp3 gene regulatory elements. This system
captures rapid changes in Foxp3 gene settings in response to
immunological cues, giving insight to Foxp3 gene regulation at
the level of hours vs. days. In contrast, fate-mapping approaches,
which have largely suggested at a cellular level Treg cells are
stable (42, 43), do not capture the “real-time” changes in
Foxp3 gene activity which may greatly influence Treg function
(41).
FOXP3-TOCKY REVEALS EFFECTOR
TREG DIFFERENTIATION AND IDENTIFIES
PTREG
We have revealed that mature Foxp3 expressers tune their
Foxp3 gene setting to a temporally persistent state to control
the resolution of skin inflammation. Thus, our recent data
suggest that studying Foxp3 as a binary marker (i.e., to identify
Treg and non-Treg) can lose biological information. Upon
immunization we observed dramatic changes in the activity of
Foxp3 transcription in various T-cell populations. At sites of
inflammation (which are the relevant comparison for JIA) Treg
increase transcription of Foxp3 in a Foxp3-protein dependent
fashion (41). This form of Foxp3 autoregulation is key to driving
what has been previously called the effector (e)Treg response,
where cells display enhanced expression of immunoregulatory
molecules, such as IL-10 and CTLA4. Thus, purely based on a
molecular readout—the activity of the Foxp3 gene—we could
identify the major features of previously coined “quiescent” Treg
and effector (e)Treg subsets (Figure 2).
Foxp3-Tocky mice allow visualization of the earliest stages
of p Treg development during physiological T-cell responses.
We reported an increased proportion of T-cells acquire de
novo Foxp3 expression within inflamed skin compared to non-
inflamed sites, during contact hypersensitivity. The biological
significance of this is still to be fully determined, but we propose
that induction of Foxp3 may be an important part of the
resolution of T-cell responses through the intrinsic regulation of
Tconv (16, 41).
POST-TRANSLATIONAL CONTROL OF
FOXP3
Aside from the transcriptional control of Foxp3, insight into the
post-translational control of Foxp3 protein has been revealed
over the past few years (44). Foxp3 protein has been shown
to be polyubiquitinated at multiple lysine residues, which can
lead to its proteasome-mediated degradation (44, 45). This
process appears to be regulated by the activity of two enzymes,
the deubiquitinase USP7 (44) and E3 ubiquitin ligase STUB1
(45). Here the authors of the studies were able to show that
inflammatory cytokines, such as IL-6 [which is elevated in JIA
synovial fluid (46)] could repress USP7 expression, resulting
in increased turnover of Foxp3 and loss of Treg control of
inflammation. These findings have led to the suggestion that
small molecular inhibitors of this process could improve the
stabilization of Foxp3 protein in cells, and therefore their
functions (47).
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FIGURE 2 | Transcriptional dynamics of Foxp3 define functional Treg profiles. (A) The Tocky system [adapted from (39)] identifies different temporal expression
patterns of the Foxp3 gene. Here a schematic is shown, illustrating how the Tocky system’s timer locus approach can be used to identify different dynamics of Foxp3
expression based on the position of cells within a theoretical flow cytometric Timer-blue and Timer-red two-dimensional space: New expressers are pure blue,
gradually acquiring red fluorescence after 4–8 h, and moving to the New-Persistent transitional (NP-t) locus. Cells which continually transcribe Foxp3, accumulate in
the blue+ red+ diagonal, called Persistent. And cells that have recently ceased Foxp3 transcription are located in the pure red Arrested locus. As Foxp3 gene activity
changes, cells can move between Arrested and Persistent zones within the Persistent-Arrested transitional (PA-t) locus. (B) Summary of Treg Foxp3 gene dynamics
under different immunological contexts. In steady state, Treg exhibit intermittent Foxp3 gene activity, and express lower levels of CD25, GITR, OX40, and IL-10. Upon
immune challenge, responsive Treg increase their Foxp3 transcriptional activity to a temporally persistent dynamic, which drives the Treg effector functions.
FOXP3 MOLECULAR “TUNING” FOR
THERAPY
Foxp3+ T-cells have a large number of molecules that have been
proposed as surrogate markers, such as high CD25 expression
and low CD127 (1) (the IL-7 receptor alpha chain). In addition,
they have also been shown to express high levels of the
Tumor necrosis factor receptor superfamily members, which
are important for their thymic development (48). Indeed, it
has been known for over 15 years that glucocorticoid-induced
TNFR-related protein (GITR) is a marker of thymic CD4+
CD25+ subsets and targeting this membrane receptor with a
monoclonal antibody could alter the course of autoimmunity
(49). Using the Foxp3-Tocky tool, we have been able to give a
dynamic perspective to common Treg cell surface markers (41).
We were able to classify membrane receptors according to their
relationship to Foxp3 transcriptional activity, revealing that they
can be classified into two main groups. Group I [containing
amongst others TNFRII, C-C chemokine receptor type four
(CCR4), CCR5] are high on activated T-cells and new Foxp3
expressers and remain high whilst active Foxp3 transcription
occurs. We could show that the targeting of a marker within this
group (TNFRII) was able to increase the proportion of T-cells
acquiring new Foxp3 expression. Group II (containing amongst
others CD25, OX40, and GITR) membrane receptors appeared
to parallel the activity of Foxp3 transcription and increased as T-
cells moved into persistent dynamics of Foxp3 Transcription (i.e.,
eTreg phenotype). Very interestingly, expression levels of these
molecules fell considerably in T-cells with low or arrested Foxp3
transcriptional activity, implying they are selective to the eTreg-
type programme. OX40 was one member of this group, and
we showed that upon anti-OX40 treatment Foxp3+ T-cells were
shorter lived and “persistent” Foxp3 transcribers were reduced.
This correlated with a delay in the resolution of allergic T-
cell driven skin inflammation (41). Although these effects were
modest, and the precise mechanisms of action remain to be fully
elucidated, they show proof of concept that Foxp3 transcriptional
dynamics within T-cell populations can be modulated with
measurable changes in disease outcomes.
CONCLUSIONS AND FUTURE
DIRECTIONS
This review has highlighted the increases in our understanding
of Foxp3+ T-cell biology in JIA. Recent work revealing
how molecular pathways regulate Foxp3 protein and Foxp3
transcription should spur researchers to consider how these
findings may be translated to human disease settings. For
instance, it will be useful to determine whether the markers
identified in basic animal models also hold equally true for
humans. This could provide biomarkers to better understand
the immunological effects of biologics for the treatment of
autoimmune disorders such as JIA. In addition, given that
Foxp3 protein can autoregulate its transcription, it will be very
interesting to see whether post-translational modifications of
Foxp3 can alter the Foxp3-driven autoregulatory loop (41, 50),
and therefore enhance the Foxp3-driven T-cell programme. To
take these ideas forward, however, the fieldmay need to take a few
steps back from the cell lineage paradigm and consider how the
molecular dynamics of Foxp3-driven biology may provide new
avenues for translational research in JIA.
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